The deal promises $4.8 billion, and the remaining $1 billion is contingent on the “value opportunity” of Mirati’s pipeline, according to a Bristol Myers Squibb news release.
The cancer drugmaker’s leading asset is Krazati (adagrasib), which has accelerated FDA approval for small cell lung cancer in adults with a mutation that affects about 14% of patients with the cancer.
The companies said they plan to finalize the transaction in the first half of 2024.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
